Research Article
The Prognostic Value and Potential Mechanism of Tumor-Nutrition-Inflammation Index and Genes in Patients with Advanced Lung Cancer
Table 1
Clinical characteristics of the patients with different AGR and SIRI according to the optimized cut-off value in training dataset.
| | No. of patients (N = 136) | AGR < 1.22 (N = 64) | AGR 1.22 (N = 72) | value | SIRI < 1.60 (N = 61) | SIRI 1.60 (N = 75) | value |
| Gender | | | | 0.492 | | | 0.002 | Female | 40 (29.4%) | 17 (26.6%) | 23 (31.9%) | | 26 (42.6%) | 14 (18.7%) | | Male | 96 (70.6%) | 47 (73.4%) | 49 (68.1%) | | 35 (57.4%) | 61 (81.3%) | | Age | | | | 0.089 | | | 0.875 | 60 | 37 (27.2%) | 13 (20.3%) | 24 (33.3%) | | 17 (27.9%) | 20 (26.7%) | | >60 | 99 (72.8%) | 51 (79.7%) | 48 (66.7%) | | 44 (72.1%) | 55 (73.3%) | | History of LC operation | | | | 0.005 | | | 0.135 | No | 102 (75.0%) | 55 (85.9%) | 47 (65.3%) | | 42 (68.9%) | 60 (80.0%) | | Yes | 34 (25.0%) | 9 (14.1%) | 25 (34.7%) | | 19 (31.1%) | 15 (20.0%) | | Differentiation | | | | 0.172 | | | 0.078 | Poor | 36 (26.5%) | 19 (29.7%) | 17 (23.6%) | | 12 (19.7%) | 24 (32.0%) | | Moderately well | 13 (9.6%) | 3 (4.7%) | 10 (13.9%) | | 9 (14.8%) | 4 (5.3%) | | Unknown | 87 (64.0%) | 42 (65.6%) | 45 (62.5%) | | 40 (65.6%) | 47 (62.7%) | | Pathology | | | | 0.7 | | | 0.008 | Adenocarcinoma | 72 (52.9%) | 35 (54.7%) | 37 (51.4%) | | 40 (65.6%) | 32 (42.7%) | | Nonadenocarcinoma | 64 (47.1%) | 29 (45.3%) | 35 (48.6%) | | 21 (34.4%) | 43 (57.3%) | | Mutation | | | | 0.822 | | | 0.204 | Positive | 56 (41.2%) | 28 (43.8%) | 28 (38.9%) | | 30 (49.2%) | 26 (34.7%) | | Negative | 41 (30.1%) | 19 (29.7%) | 22 (30.6%) | | 17 (27.9%) | 24 (32.0%) | | Unknown | 39 (28.7%) | 17 (26.6%) | 22 (30.6%) | | 14 (23.0%) | 25 (33.3%) | | Bone metastasis | | | | 0.763 | | | 0.179 | No | 114 (83.8%) | 53 (82.8%) | 61 (84.7%) | | 54 (88.5%) | 60 (80.0%) | | Yes | 22 (16.2%) | 11 (17.2%) | 11 (15.3%) | | 7 (11.5%) | 15 (20.0%) | | Brain metastasis | | | | 0.869 | | | 0.596 | No | 114 (83.8%) | 54 (84.4%) | 60 (83.3%) | | 50 (82.0%) | 64 (85.3%) | | Yes | 22 (16.2%) | 10 (15.6%) | 12 (16.7%) | | 11 (18.0%) | 11 (14.7%) | | Adrenal metastasis | | | | 0.413 | | | 0.707 | No | 124 (91.2%) | 57 (89.1%) | 67 (93.1%) | | 55 (90.2%) | 69 (92.0%) | | Yes | 12 (8.8%) | 7 (10.9%) | 5 (6.9%) | | 6 (19.8%) | 6 (8.0%) | | Liver metastasis | | | | 0.514 | | | 0.097 | No | 123 (90.4%) | 59 (92.2%) | 64 (88.9%) | | 58 (95.1%) | 65 (86.7%) | | Yes | 13 (9.6%) | 5 (7.8%) | 8 (11.1%) | | 3 (4.9%) | 10 (13.3%) | | History of smoke | | | | 0.479 | | | 0.112 | No | 70 (51.5%) | 35 (54.7%) | 35 (48.6%) | | 36 (59.0%) | 34 (45.3%) | | Yes | 66 (48.5%) | 29 (45.3%) | 37 (51.4%) | | 25 (41.0%) | 41 (54.7%) | | History of alcohol | | | | 0.427 | | | 0.619 | No | 102 (75.0%) | 50 (78.1%) | 52 (72.2%) | | 47 (77.0%) | 55 (73.3%) | | Yes | 34 (25.0%) | 14 (21.9%) | 20 (27.8%) | | 14 (23.0%) | 20 (26.7%) | | Hypertension | | | | 0.444 | | | 0.264 | No | 89 (65.4%) | 44 (68.8%) | 45 (62.5%) | | 43 (70.5%) | 46 (61.3%) | | Yes | 47 (34.6%) | 20 (31.2%) | 27 (37.5%) | | 18 (29.5%) | 29 (38.7%) | | Diabetes | | | | 0.606 | | | 0.881 | No | 121 (89.0%) | 56 (87.5%) | 65 (90.3%) | | 54 (88.5%) | 67 (89.3%) | | Yes | 15 (11.0%) | 8 (12.5%) | 7 (9.7%) | | 7 (11.5%) | 8 (10.7%) | | BMI | | | | 0.008 | | | 0.407 | <18.5 | 12 (8.8%) | 10 (15.6%) | 2 (2.8%) | | 4 (6.6%) | 8 (10.7%) | | 18.5 | 124 (91.2%) | 54 (84.4%) | 70 (97.2%) | | 57 (93.4%) | 67 (89.3%) | | CEA | | | | 0.018 | | | 0.88 | 5 | 57 (41.9%) | 20 (31.2%) | 37 (51.4%) | | 26 (42.6%) | 31 (41.3%) | | >5 | 79 (58.1%) | 44 (68.8%) | 35 (48.6%) | | 35 (57.4%) | 44 (58.7%) | | CA199 | | | | 0.078 | | | 0.602 | 43 | 95 (69.9%) | 40 (62.5%) | 55 (76.4%) | | 44 (72.1%) | 51 (68.0%) | | >43 | 41 (30.1%) | 24 (37.5%) | 17 (23.6%) | | 17 (27.9%) | 24 (32.0%) | | SCC | | | | 0.113 | | | 0.361 | 1.5 | 88 (64.7%) | 37 (57.8%) | 51 (70.8%) | | 42 (68.9%) | 46 (61.3%) | | >1.5 | 48 (35.3%) | 27 (42.2%) | 21 (29.2%) | | 19 (31.0%) | 29 (38.7%) | | AFP | | | | 0.734 | | | 0.589 | 7 | 111 (81.6%) | 53 (82.8%) | 58 (80.6%) | | 51 (83.6%) | 60 (80.0%) | | >7 | 25 (18.4%) | 11 (17.2%) | 14 (19.4%) | | 10 (16.4%) | 15 (20.0%) | | CRP | | | | <0.001 | | | <0.001 | 5.5 | 63 (46.3%) | 14 (21.9%) | 49 (68.1%) | | 40 (65.6%) | 23 (30.7%) | | >5.5 | 73 (53.7%) | 50 (78.1%) | 23 (31.9%) | | 21 (34.4%) | 52 (69.3%) | |
|
|